Liquid Chromatography–Tandem Mass Spectrometry Quantification of Globotriaosylceramide in Plasma for Long-Term Monitoring of Fabry Patients Treated with Enzyme Replacement Therapy-Reference-Cited by-同舟云学术

Liquid Chromatography–Tandem Mass Spectrometry Quantification of Globotriaosylceramide in Plasma for Long-Term Monitoring of Fabry Patients Treated with Enzyme Replacement Therapy

Published:2005-01-01 Issue:1 Volume:51 Page:237-240
ISSN:0009-9147
Container-title:Clinical Chemistry
language:en
Short-container-title:

Author:

Roddy Thomas P¹,Nelson Bryant C¹,Sung Crystal CC¹,Araghi Shaparak¹,Wilkens Dennis¹,Zhang X Kate²,Thomas John J²,Richards Susan M¹

Affiliation:

1. Clinical Laboratory Science, and

2. Protein Characterization & Modification, Genzyme Corporation, One Mountain Road, Framingham, MA 01701-9322

Publisher

Oxford University Press (OUP)

Subject

Biochemistry, medical,Clinical Biochemistry

Link

http://academic.oup.com/clinchem/article-pdf/51/1/237/32682156/clinchem0237.pdf

Reference21 articles.

1. Desnick RJ, Ioannou YA, Eng CM. α-Galactosidase A deficiency: Fabry disease. Scriver CR Beaudet AL Sly WS Valle D eds. The metabolic and molecular bases of inherited disease 8th ed 2001:3733-3774 McGraw-Hill New York. .

2. Desnick RJ, Brady R, Barranger J, Collins AJ, Germain DP, Goldman M, et al. Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med2003;138:338-346.

3. Thurberg BL, Rennke H, Colvin RB, Dikman S, Gordon RE, Collins AB, et al. Globotriaosylceramide accumlation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. Kidney Int2002;62:1933-1946.

4. Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S, et al. Safety and efficacy of recombinant human α-galactosidase A: replacement therapy in Fabry’s disease. New Engl J Med2001;345:9-16.

5. Grabowski GA, Hopkin RJ. Enzyme therapy for lysosomal storage disease: principles, practice, and prospects. Annu Rev Genomics Hum Genet2003;4:403-436.

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Plasma and platelet lipidome changes in Fabry disease;Clinica Chimica Acta;2024-08

2. Reduction in kidney function decline and risk of severe clinical events in agalsidase beta–treated Fabry disease patients: a matched analysis from the Fabry Registry;Clinical Kidney Journal;2024-07-02

3. Enzyme replacement therapy in two patients with classic Fabry disease from the same family tree: Two case reports;World Journal of Clinical Cases;2023-05-26

4. Systematic cascade screening in the Danish Fabry Disease Centre: 20 years of a national single-centre experience;PLOS ONE;2022-11-16

5. Hearing loss in fabry disease: A 16 year follow-up study of the Danish nationwide cohort;Molecular Genetics and Metabolism Reports;2022-06